01—Abstract
Summary
Summary of the 10-K filed February 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Regeneron (REGN) reported record 2024 results: total revenues rose 8% to $14.20 billiona (from $13.12 billion), and net income grew 12% to $4.41 billion, with diluted EPS of $38.34 (up from $34.77).
Growth was driven primarily by collaboration revenue, especially Sanofi's share of Dupixent profits ($4.53 billionb, up 19%), and by Dupixent global sales, which reached $14.1 billion. Other drivers included Libtayo global sales of $1.22 billion (up 41%) and EYLEA HD's U.S. launch, which generated $1.20 billion in its first full year. Offsetting these gains, U.S. EYLEA sales fell 17% as biosimilar competition arrived after the May 2024 exclusivity expiry, and U.S. EYLEA HD and EYLEA combined net sales rose only 1% to $5.97 billion.
Profitability was pressured by higher operating expenses, which rose 13% to $10.21 billionc, driven by R&D of $5.13 billion (up 16%) and SG&A of $2.95 billion (up 4%) tied to the EYLEA HD launch and international expansion. Income from operations declined about 1% to $3.99 billion. Net income was supported by $844 million in other income, mainly $711 million of interest income, and by a low 7.7% effective tax rate.
Cash generation stayed strong at $4.42 billiond of operating cash flow, though free cash flow was lower after $756 million of capex. Cash and marketable securities totaled $17.9 billion against $2.7 billion of debt and finance lease obligations. Management signaled a shift in capital return policy: the board authorized a new $3.0 billion buyback in February 2025 and initiated a quarterly dividend of $0.88 per share, a first for the company.
Investors should weigh concentration risk: EYLEA franchise and Dupixent together account for a large share of revenue, and the company faces significant legal exposure, including DOJ False Claims Act and Anti-Kickback matters related to EYLEA, Praluent antitrust litigation, and a new securities class action. Capital expenditures are expected to be $850 million to $975 million in 2025, and the pipeline includes several 2025 regulatory decisions, such as linvoseltamab, Dupixent CSU, and EYLEA HD for RVO.
02—Key points
Key Highlights
- Revenue grew 8% to $14.20B in 2024, led by collaboration revenue of $6.06B (up 10%), with Sanofi collaboration revenue up 19% to $4.53B.
- Net income rose 12% to $4.41B and diluted EPS increased 10% to $38.34, helped by $844M of other income including $711M of interest income and a 7.7% effective tax rate.
- Dupixent is the main growth engine, with global net sales of $14.15B (up 22%) and U.S. sales of $10.4B; Regeneron's profit share from Dupixent and Kevzara reached $3.92B.
- U.S. EYLEA franchise sales were flat overall at $5.97B, as EYLEA HD ($1.20B) offset a 17% decline in EYLEA U.S. sales following biosimilar entry after May 2024.
- Libtayo global sales increased 41% to $1.22B, and product sales overall rose 8% to $7.63B.
- Operating expenses rose 13% to $10.21B, with R&D up 16% to $5.13B, so income from operations was roughly flat at $3.99B.
- Capital return expanded: the company initiated its first quarterly dividend ($0.88/share), authorized a new $3.0B buyback in February 2025, and had $1.9B remaining under the April 2024 program at year-end.
- Liquidity remained strong with $17.9B in cash and marketable securities against $2.7B of debt and finance lease obligations, though legal and concentration risks remain significant.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 5, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $14.20B$13.12B | +8.3% |
| R&D Expenses | $5.13B$4.44B | +15.6% |
| SG&A Expenses | $2.95B$2.63B | +12.3% |
| Operating Expenses | $10.21B$9.07B | +12.6% |
| Operating Income | $3.99B$4.05B | −1.4% |
| Net Income | $4.41B$3.95B | +11.6% |
| EPS (Basic) | $40.90$37.05 | +10.4% |
| EPS (Diluted) | $38.34$34.77 | +10.3% |
| Shares Outstanding (Basic) | 107.90M106.70M | +1.1% |
| Shares Outstanding (Diluted) | 115.10M113.70M | +1.2% |
05—Questions
Frequently Asked Questions
How concentrated is Regeneron's revenue in its key products?
Concentration is high. EYLEA HD and EYLEA U.S. sales represented 42% of 2024 total revenue, and Sanofi collaboration revenue, mostly Dupixent profit share, represented 32%. Two U.S. distributors accounted for 74% of gross product revenue, and two customers held 79% of net trade receivables.
What happened to EYLEA sales in 2024, and what does biosimilar competition mean?
U.S. EYLEA sales fell 17% to $4.77B after the regulatory exclusivity period ended in May 2024 and a biosimilar launched in the U.S. Management expects further biosimilar entry in the U.S. and ex-U.S. markets, which could reduce Bayer collaboration revenue. EYLEA HD growth is intended to offset this decline, but management said the offset is uncertain.
What are the main legal risks investors should monitor?
The most material items include DOJ civil complaints under the False Claims Act and Anti-Kickback Statute tied to EYLEA, Praluent and other products, and related payor RICO lawsuits. There is also a new federal securities class action filed in January 2025, derivative suits, and a lawsuit against Sanofi over information access and audit rights. The company says it cannot estimate the possible loss for these matters.
Is Regeneron's capital allocation shifting toward shareholder returns?
Yes. Regeneron had not paid dividends before 2025. In February 2025 it started a quarterly dividend of $0.88 per share and authorized an additional $3.0B repurchase program. It repurchased $2.6B of stock in 2024, but capex is rising, with guidance of $850M to $975M for 2025 to support facility expansion.
06—Continue